![Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab]()
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabGandara, David R.; Paul, Sarah M.; Kowanetz, Marcin; Schleifman, Erica; Zou, Wei; Li, Yan; Rittmeyer, Achim; Fehrenbacher, Louis; Otto, Geoff; Malboeuf, Christine; Lieber, Daniel S.; Lipson, Doron; Silterra, Jacob; Amler, Lukas; Riehl, Todd; Cummings, Craig A.; Hegde, Priti S.; Sandler, Alan; Ballinger, Marcus; Fabrizio, David; Mok, Tony; Shames, David S. · Nature Medicine · 2018